PL3075395T3 - Prolek adrenomeduliny oparty na glikolu polietylenowym i jego zastosowanie - Google Patents

Prolek adrenomeduliny oparty na glikolu polietylenowym i jego zastosowanie

Info

Publication number
PL3075395T3
PL3075395T3 PL15192265T PL15192265T PL3075395T3 PL 3075395 T3 PL3075395 T3 PL 3075395T3 PL 15192265 T PL15192265 T PL 15192265T PL 15192265 T PL15192265 T PL 15192265T PL 3075395 T3 PL3075395 T3 PL 3075395T3
Authority
PL
Poland
Prior art keywords
adrenomedullin
polyethylene glycol
glycol based
based prodrug
prodrug
Prior art date
Application number
PL15192265T
Other languages
English (en)
Inventor
Ingo Flamme
Johannes KÖBBERLING
Hans-Georg Lerchen
Nils Griebenow
Rudolf Schohe-Loop
Sven WITTROCK
Maria KÖLLNBERGER
Frank Wunder
Gorden Redlich
Andreas Knorr
July MARLEY
Iain PRITCHARD
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property Gmbh filed Critical Bayer Pharma Aktiengesellschaft
Publication of PL3075395T3 publication Critical patent/PL3075395T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
PL15192265T 2011-11-03 2012-10-30 Prolek adrenomeduliny oparty na glikolu polietylenowym i jego zastosowanie PL3075395T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187735 2011-11-03
EP12783566.8A EP2773376B1 (en) 2011-11-03 2012-10-30 Polyethylene glycol based prodrug of adrenomedullin and use thereof
EP15192265.5A EP3075395B1 (en) 2011-11-03 2012-10-30 Polyethylene glycol based prodrug of adrenomedullin and use thereof

Publications (1)

Publication Number Publication Date
PL3075395T3 true PL3075395T3 (pl) 2018-04-30

Family

ID=47146369

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12783566T PL2773376T3 (pl) 2011-11-03 2012-10-30 Oparty na glikolu polietylenowym prolek adrenomeduliny i jego zastosowanie
PL15192265T PL3075395T3 (pl) 2011-11-03 2012-10-30 Prolek adrenomeduliny oparty na glikolu polietylenowym i jego zastosowanie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12783566T PL2773376T3 (pl) 2011-11-03 2012-10-30 Oparty na glikolu polietylenowym prolek adrenomeduliny i jego zastosowanie

Country Status (45)

Country Link
US (3) US9603936B2 (pl)
EP (2) EP2773376B1 (pl)
JP (2) JP5995984B2 (pl)
KR (2) KR102004668B1 (pl)
CN (2) CN103998063B (pl)
AR (2) AR088582A1 (pl)
AU (2) AU2012331244B2 (pl)
BR (1) BR112014010708B1 (pl)
CA (1) CA2854134C (pl)
CL (1) CL2014000948A1 (pl)
CO (1) CO7020863A2 (pl)
CR (1) CR20140184A (pl)
CU (1) CU24184B1 (pl)
CY (2) CY1117354T1 (pl)
DK (2) DK2773376T3 (pl)
DO (2) DOP2014000078A (pl)
EA (2) EA025631B1 (pl)
EC (2) ECSP14013326A (pl)
ES (2) ES2659195T3 (pl)
GT (1) GT201400085A (pl)
HK (1) HK1246147A1 (pl)
HR (2) HRP20160285T1 (pl)
HU (2) HUE027333T2 (pl)
IL (3) IL232037B (pl)
IN (1) IN2014CN03290A (pl)
JO (2) JOP20190001B1 (pl)
LT (1) LT3075395T (pl)
MA (1) MA35618B1 (pl)
ME (1) ME02379B (pl)
MX (2) MX361287B (pl)
MY (2) MY173372A (pl)
NO (1) NO3075395T3 (pl)
PE (2) PE20141219A1 (pl)
PL (2) PL2773376T3 (pl)
PT (1) PT3075395T (pl)
RS (2) RS54623B1 (pl)
SG (2) SG10201607516SA (pl)
SI (2) SI2773376T1 (pl)
TN (1) TN2014000185A1 (pl)
TR (1) TR201802124T4 (pl)
TW (2) TWI583396B (pl)
UA (1) UA111098C2 (pl)
UY (2) UY34419A (pl)
WO (1) WO2013064508A1 (pl)
ZA (1) ZA201600434B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150000464A (ko) * 2011-11-03 2015-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
CN106164088B (zh) * 2014-03-20 2021-11-23 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
CU20170038A7 (es) * 2014-09-26 2017-10-05 Bayer Pharma AG Derivados de adrenomedulina estabililzados especialmente útiles en el tratamiento y/o prevención de trastornos cardiovasculares, edematosos y/o inflamatorios
WO2017047788A1 (ja) * 2015-09-18 2017-03-23 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
US11578112B2 (en) 2017-03-29 2023-02-14 University Of Miyazaki Long-acting adrenomedullin derivative conjugated with Fc region of immunoglobulin
GB201707938D0 (en) * 2017-05-17 2017-06-28 Univ Sheffield Compounds
JP2022537369A (ja) 2019-06-18 2022-08-25 バイエル アクチェンゲゼルシャフト 長期安定化のためのアドレノメデュリン－類似体およびその使用
JPWO2021112220A1 (pl) * 2019-12-05 2021-06-10
BR112022017588A2 (pt) 2020-04-03 2022-10-18 Bayer Ag Formulações farmacêuticas de profármacos de adrenomedulina à base de polietileno glicol e uso
CN115484987A (zh) 2020-04-03 2022-12-16 拜耳公司 液体药物制剂聚乙二醇基肾上腺髓质素前药和用途
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
CA3229418A1 (en) 2021-08-20 2023-02-23 Bayer Aktiengesellschaft Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2005009768A1 (en) 2003-07-23 2005-02-03 Meggitt Aerospace Equipment Composite seal
CA2940803A1 (en) 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
DK1749026T3 (da) 2004-05-24 2012-02-27 Inst Cardiologie Montreal Mærkede adrenomedullinderivater og deres anvendelse til billeddannelse og terapi
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
EP2091570A1 (en) * 2006-12-20 2009-08-26 GE Healthcare AS Contrast agents
WO2008138141A1 (en) 2007-05-11 2008-11-20 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
KR20150000464A (ko) * 2011-11-03 2015-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커

Also Published As

Publication number Publication date
ECSP14013326A (es) 2014-05-31
GT201400085A (es) 2015-03-05
EA201400528A1 (ru) 2014-10-30
US9649363B2 (en) 2017-05-16
CN107412740B (zh) 2021-02-09
US9603936B2 (en) 2017-03-28
EP3075395A1 (en) 2016-10-05
TR201802124T4 (tr) 2018-03-21
EA025631B1 (ru) 2017-01-30
NO3075395T3 (pl) 2018-04-21
EP2773376A1 (en) 2014-09-10
MX2014004384A (es) 2014-04-30
CU20140051A7 (es) 2014-10-02
BR112014010708A2 (pt) 2017-04-25
KR20180108892A (ko) 2018-10-04
EA029410B1 (ru) 2018-03-30
ES2568063T3 (es) 2016-04-27
ZA201600434B (en) 2017-05-31
AU2012331244B2 (en) 2017-06-15
DK3075395T3 (en) 2018-02-19
NZ622997A (en) 2015-12-24
DOP2018000203A (es) 2018-10-15
HRP20160285T1 (hr) 2016-04-22
IL252281B (en) 2021-01-31
SI3075395T1 (en) 2018-03-30
AR088582A1 (es) 2014-06-18
ECSP18071104A (es) 2018-10-31
IN2014CN03290A (pl) 2015-07-03
UY34419A (es) 2013-05-31
CU24184B1 (es) 2016-07-29
IL258229B (en) 2020-02-27
SG11201400924TA (en) 2014-09-26
HUE036535T2 (hu) 2018-07-30
PE20141219A1 (es) 2014-09-13
SI2773376T1 (sl) 2016-05-31
DOP2014000078A (es) 2014-07-15
CL2014000948A1 (es) 2014-09-05
US10035818B2 (en) 2018-07-31
AU2017203423A1 (en) 2017-06-08
HUE027333T2 (en) 2016-09-28
EA201600495A1 (ru) 2016-10-31
IL232037A0 (en) 2014-05-28
PL2773376T3 (pl) 2016-07-29
CY1117354T1 (el) 2017-04-26
MX350341B (es) 2017-09-04
CY1119897T1 (el) 2018-06-27
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30
IL252281A0 (en) 2017-08-31
AU2017203423B2 (en) 2019-01-31
MY194197A (en) 2022-11-21
HK1246147A1 (zh) 2018-09-07
JOP20190001A1 (ar) 2017-06-16
TW201720467A (zh) 2017-06-16
KR101965467B1 (ko) 2019-04-03
UY37922A (es) 2018-11-30
CA2854134C (en) 2020-04-21
RS54623B1 (en) 2016-08-31
TWI653051B (zh) 2019-03-11
LT3075395T (lt) 2018-02-26
TW201332573A (zh) 2013-08-16
US20170204137A1 (en) 2017-07-20
IL258229A (en) 2018-06-28
DK2773376T3 (en) 2016-04-18
AU2012331244A1 (en) 2014-04-17
MY173372A (en) 2020-01-21
SG10201607516SA (en) 2016-10-28
JP2014532682A (ja) 2014-12-08
PT3075395T (pt) 2018-02-13
HRP20180319T1 (hr) 2018-03-23
PE20181493A1 (es) 2018-09-18
US20140287984A1 (en) 2014-09-25
AR113830A2 (es) 2020-06-17
CN107412740A (zh) 2017-12-01
IL232037B (en) 2018-12-31
KR102004668B1 (ko) 2019-07-26
JP5995984B2 (ja) 2016-09-21
NZ714621A (en) 2017-10-27
EP2773376B1 (en) 2016-01-13
MA35618B1 (fr) 2014-11-01
WO2013064508A1 (en) 2013-05-10
CA2854134A1 (en) 2013-05-10
KR20150000462A (ko) 2015-01-02
CN103998063A (zh) 2014-08-20
ES2659195T3 (es) 2018-03-14
UA111098C2 (uk) 2016-03-25
TWI583396B (zh) 2017-05-21
JO3385B1 (ar) 2019-03-13
EP3075395B1 (en) 2017-11-22
BR112014010708B1 (pt) 2021-03-02
CR20140184A (es) 2014-05-27
CN103998063B (zh) 2016-09-21
US20160367636A1 (en) 2016-12-22
CO7020863A2 (es) 2014-08-11
JP2017014264A (ja) 2017-01-19
JP6177975B2 (ja) 2017-08-09
JOP20190001B1 (ar) 2022-03-14
ME02379B (me) 2016-06-20
RS56819B1 (sr) 2018-04-30

Similar Documents

Publication Publication Date Title
HK1246147A1 (zh) 聚乙二醇基腎上腺髓質素前藥及其用途
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
EP2709554A4 (en) TEMPORARY SUPPORTING ARROW WITH A COMBINATION OF FEATURES AND PROVISIONAL FUNCTIONS
PT2761083T (pt) Papel e métodos para produzir papel
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
HK1202244A1 (en) Prebiotic formulations and methods of use
EP2758183A4 (en) BIODEGRADABLE COMPOSITIONS AND THEIR USE
HK1202112A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
GB201111705D0 (en) Compounds and their use
EP2635260A4 (en) COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
IL225892A0 (en) Formulations containing polyethylene glycol
IL227924B (en) Preparations and methods of use for determining a4he
EP2753337A4 (en) COMPOSITIONS COMPRISING BETA-GLUCANS AND METHODS OF USE
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
EP2767552A4 (en) COMPOSITION AND FILM CONTAINING IT
EP2762129A4 (en) COSMETIC COMPOSITION AND COSMETIC PRODUCT
GB201114448D0 (en) Compounds and their use
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
HK1254904B (zh) 用於改變xlhed表型的組合物和方法
ZA201307230B (en) Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma-glutamyl-l-tryptophan
EP2776462A4 (en) INDOLALKYLAMINO WITHASTEROID CONJUGATES AND USE METHOD THEREFOR
IL235551A0 (en) Local anesthetic storage preparations and methods for their production
IL231477A0 (en) Degradable vehicles and their use
ZA201304053B (en) Formulations comprising polyethylene glycol